Vivani Medical’s NPM-115 Implant Shows Promising Weight Loss Results 

Photo of author
Written By Marcus Reynolds

Vivani Medical Inc (NASDAQ: VANI) made waves recently with the release of preclinical data on NPM-115, its miniature exenatide subdermal implant aimed at chronic weight management. 

The study showcased impressive weight loss effects, drawing comparisons to Novo Nordisk A/S’s (NYSE: NVO) renowned Ozempic/Wegovy injections. 

Study Findings

In a study conducted on high-fat diet-induced obese mice, NPM-115 demonstrated a remarkable weight loss of approximately 20% compared to a sham implant control after a 28-day treatment period. 

This level of weight reduction was found to be on par with the effects observed in mice treated with Novo Nordisk’s Ozempic/Wegovy injections, showcasing the efficacy of NPM-115 in combating obesity.

Credits: DepositPhotos

Supratherapeutic doses of both NPM-115 and semaglutide, the active ingredient in Ozempic/Wegovy, were administered to maximize weight-loss potential. 

Despite the differing delivery mechanisms – NPM-115 being a subdermal implant and semaglutide being injectable – both treatments yielded comparable outcomes, indicating the effectiveness of NPM-115 in promoting weight loss.

Read More: DigitalOcean Holdings Inc (DOCN) Reports Show Solid Revenue Growth and Robust Free Cash Flow in FY 2023

Successful Results 

Furthermore, in a separate study involving healthy rats, another implant, NPM-119, delivered promising results for type 2 diabetes treatment. A single administration of NPM-119 resulted in body weights approximately 25% lower than those in the control group after 15 weeks of treatment. 

With a duration of effect expected to last six months, NPM-119 demonstrated consistent release of exenatide, suggesting its potential as a long-term solution for diabetes management.

Implications and Future Prospects

The positive outcomes observed in these preclinical studies bode well for Vivani Medical’s strategic shift toward prioritizing obesity implants. 

The durability of the weight loss effect demonstrated by NPM-119 provides optimism for future studies utilizing NPM-115, a higher-dose version of a similar product. Additionally, NPM-139, another implant

in development for chronic weight management, further underscores the company’s commitment to addressing the obesity epidemic.

Moreover, these findings shed light on the untapped potential of exenatide in humans, particularly in currently marketed products such as AstraZeneca Plc’s Byetta and Bydureon. 

Also Read: GoodRx Holdings Inc (GDRX) Delivers Mixed Results for Q4 and Full Year 2023: Is it Time to Buy?

Hindrances to Evaluation

The limitations associated with adherence and dosing in these products may have hindered a comprehensive evaluation of exenatide’s weight loss potential, making implants like NPM-115 and NPM-139 promising alternatives for patients.

Successful Preclinical Studies 

The success of NPM-115 and NPM-119 in preclinical studies opens up exciting possibilities for clinical trials and eventual regulatory approval. If these implants continue to demonstrate efficacy and safety in human trials, they could revolutionize the treatment landscape for obesity and type 2 diabetes. 

Furthermore, the strategic shift towards prioritizing obesity implants reflects the growing recognition of obesity as a chronic disease requiring innovative treatment approaches. 

In addition to their potential clinical benefits, Vivani Medical’s implants also hold promise from a business perspective. If successfully brought to market, these implants could generate substantial revenue for the company and establish it as a leader in the field of obesity and diabetes treatment. 

Significant Advancements in Fields of Weight Management

Vivani Medical’s groundbreaking preclinical studies on NPM-115 and NPM-119 represent significant advancements in the fields of weight management and diabetes treatment. 

Credits: DepositPhotos

With promising results comparable to established treatments like Ozempic/Wegovy, these implants offer new hope for patients struggling with obesity and type 2 diabetes. 

Read Next: Consensus Cloud Solutions (NASDAQ: CCSI) is an Intriguing Investment Opportunity 


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.